跳转至内容
Merck

1000818

USP

醋酸阿比特龙

United States Pharmacopeia (USP) Reference Standard

别名:

17-(吡啶-3-基)雄甾-5,16-二烯-3β-乙酸基

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C26H33NO2
分子量:
391.55
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

abiraterone

製造商/商標名

USP

應用

pharmaceutical (small molecule)

形式

neat

SMILES 字串

C[C@]12C(C[C@@H](OC(C)=O)CC2)=CC[C@]3([H])[C@]1([H])CC[C@@]4(C)[C@@]3([H])CC=C4C5=CC=CN=C5

InChI

1S/C26H33NO2/c1-17(28)29-20-10-12-25(2)19(15-20)6-7-21-23-9-8-22(18-5-4-14-27-16-18)26(23,3)13-11-24(21)25/h4-6,8,14,16,20-21,23-24H,7,9-13,15H2,1-3H3/t20-,21-,23-,24-,25-,26+/m0/s1

InChI 密鑰

UVIQSJCZCSLXRZ-UBUQANBQSA-N

基因資訊

human ... CYP17A1(1586)

正在寻找类似产品? 访问 产品对比指南

一般說明

Abiraterone acetate is a pro-drug of abiraterone and a potent inhibitor of the enzyme CYP17, required for androgen biosynthesis in the adrenal glands, testes and prostate tissue.

應用

Abiraterone acetate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Abiraterone Acetate Tablets

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

象形圖

Health hazardEnvironment

訊號詞

Danger

危險聲明

危險分類

Aquatic Chronic 1 - Repr. 1B - STOT RE 2

標靶器官

Endocrine system

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
Danila.CD, et al.
Journal of Clinical Oncology, 28(9), 1496-1501 (2010)
Ryan.JC, et al.
Journal of Clinical Oncology, 28(9), 1481-1488 (2010)
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response
Ryan.JC, et al.
Clinical Cancer Research, 14(7), 4854-4861 (2011)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门